Prevention of diabetes by thymic hormone in alloxan-treated rats
We investigated the effects of facteur thymique sérique (FTS), a thymic peptide hormone, on alloxan- and streptozotocin-induced diabetes in rats. Pretreatment with intravenous injection of FTS significantly suppressed both alloxan- and streptozotocin-induced hyperglycemia. The effects of FTS were ti...
Gespeichert in:
| Veröffentlicht in: | European journal of pharmacology 1994-05, Vol.257 (1), p.39-46 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 46 |
|---|---|
| container_issue | 1 |
| container_start_page | 39 |
| container_title | European journal of pharmacology |
| container_volume | 257 |
| creator | Yamanouchi, Toshikazu Moromizato, Hitoshi Kojima, Shuhji Shinohara, Takaomi Sekino, Nori Minoda, Susumu Miyashita, Hideo Akaoka, Ieo |
| description | We investigated the effects of facteur thymique sérique (FTS), a thymic peptide hormone, on alloxan- and streptozotocin-induced diabetes in rats. Pretreatment with intravenous injection of FTS significantly suppressed both alloxan- and streptozotocin-induced hyperglycemia. The effects of FTS were time dependent. FTS suppressed hyperglycemia in a dose range of 1–6600 μg/kg. Alloxan-induced hyperglycemia was completely prevented when FTS was injected in doses of 40–50 μg/kg 1 min before injection of alloxan. Histological examination of islet areas showed that alloxan-induced destruction of β-cells was inhibited by FTS. FTS had no significant effects on lymphocyte subsets and immunity-related cells or on plasma superoxide dismutase activity and total glutathione level. The blood half-life time of exogenously injected FTS was short (2–3 min), indicating acute internalization of FTS into pancreatic β-cells. Our results suggested that FTS acutely and directly blocks some initial effect of alloxan, preventing the destruction of β-cells. |
| doi_str_mv | 10.1016/0014-2999(94)90691-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76695451</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0014299994906912</els_id><sourcerecordid>76695451</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-b4d1e18ff613c51449ab8cbd9b7c1ba6e632daf3bbc678805cc2a21c36db678d3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotX78A4U9iOhhNclms5uLKMUvKOhBzyEfszSyu6lJWuy_d2tLj54GZp53ZngQOiP4hmDCbzEmLKdCiCvBrgXmguR0D41JXYkcV4Tuo_EOOURHMX5hjEtByxEa1bimFS7H6P49wBL65Hyf-SazTmlIEDO9ytJs1TmTzXzofA-Z6zPVtv5H9XkKoBLYLKgUT9BBo9oIp9t6jD6fHj8mL_n07fl18jDNDStpyjWzBEjdNJwUpiSMCaVro63QlSFaceAFtaoptDa8qmtcGkMVJabgVg8NWxyjy83eefDfC4hJdi4aaFvVg19EWXEuSlaSAWQb0AQfY4BGzoPrVFhJguVanFxbkWsrUjD5J07SIXa-3b_QHdhdaGtqmF9s5yoa1TZB9cbFHcawqJhYX7_bYDC4WDoIMhoHvQHrApgkrXf___EL_dyJ0w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76695451</pqid></control><display><type>article</type><title>Prevention of diabetes by thymic hormone in alloxan-treated rats</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Yamanouchi, Toshikazu ; Moromizato, Hitoshi ; Kojima, Shuhji ; Shinohara, Takaomi ; Sekino, Nori ; Minoda, Susumu ; Miyashita, Hideo ; Akaoka, Ieo</creator><creatorcontrib>Yamanouchi, Toshikazu ; Moromizato, Hitoshi ; Kojima, Shuhji ; Shinohara, Takaomi ; Sekino, Nori ; Minoda, Susumu ; Miyashita, Hideo ; Akaoka, Ieo</creatorcontrib><description>We investigated the effects of facteur thymique sérique (FTS), a thymic peptide hormone, on alloxan- and streptozotocin-induced diabetes in rats. Pretreatment with intravenous injection of FTS significantly suppressed both alloxan- and streptozotocin-induced hyperglycemia. The effects of FTS were time dependent. FTS suppressed hyperglycemia in a dose range of 1–6600 μg/kg. Alloxan-induced hyperglycemia was completely prevented when FTS was injected in doses of 40–50 μg/kg 1 min before injection of alloxan. Histological examination of islet areas showed that alloxan-induced destruction of β-cells was inhibited by FTS. FTS had no significant effects on lymphocyte subsets and immunity-related cells or on plasma superoxide dismutase activity and total glutathione level. The blood half-life time of exogenously injected FTS was short (2–3 min), indicating acute internalization of FTS into pancreatic β-cells. Our results suggested that FTS acutely and directly blocks some initial effect of alloxan, preventing the destruction of β-cells.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/0014-2999(94)90691-2</identifier><identifier>PMID: 8082705</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Alloxan ; Amino Acid Sequence ; Animals ; Biological and medical sciences ; Diabetes Mellitus, Experimental - prevention & control ; Diabetes. Impaired glucose tolerance ; Dose-Response Relationship, Drug ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; FTS (facteur thymique sérique) ; Glutathione - blood ; Hyperglycemia - prevention & control ; Injections, Intravenous ; Islets of Langerhans - drug effects ; Islets of Langerhans - pathology ; Male ; Medical sciences ; Molecular Sequence Data ; Rats ; Rats, Wistar ; Spleen - drug effects ; Spleen - pathology ; Superoxide Dismutase - blood ; Thymic Factor, Circulating - pharmacokinetics ; Thymic Factor, Circulating - pharmacology ; Thymic hormone ; Thymic immunity ; Tissue Distribution</subject><ispartof>European journal of pharmacology, 1994-05, Vol.257 (1), p.39-46</ispartof><rights>1994</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-b4d1e18ff613c51449ab8cbd9b7c1ba6e632daf3bbc678805cc2a21c36db678d3</citedby><cites>FETCH-LOGICAL-c452t-b4d1e18ff613c51449ab8cbd9b7c1ba6e632daf3bbc678805cc2a21c36db678d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0014299994906912$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4097491$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8082705$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamanouchi, Toshikazu</creatorcontrib><creatorcontrib>Moromizato, Hitoshi</creatorcontrib><creatorcontrib>Kojima, Shuhji</creatorcontrib><creatorcontrib>Shinohara, Takaomi</creatorcontrib><creatorcontrib>Sekino, Nori</creatorcontrib><creatorcontrib>Minoda, Susumu</creatorcontrib><creatorcontrib>Miyashita, Hideo</creatorcontrib><creatorcontrib>Akaoka, Ieo</creatorcontrib><title>Prevention of diabetes by thymic hormone in alloxan-treated rats</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>We investigated the effects of facteur thymique sérique (FTS), a thymic peptide hormone, on alloxan- and streptozotocin-induced diabetes in rats. Pretreatment with intravenous injection of FTS significantly suppressed both alloxan- and streptozotocin-induced hyperglycemia. The effects of FTS were time dependent. FTS suppressed hyperglycemia in a dose range of 1–6600 μg/kg. Alloxan-induced hyperglycemia was completely prevented when FTS was injected in doses of 40–50 μg/kg 1 min before injection of alloxan. Histological examination of islet areas showed that alloxan-induced destruction of β-cells was inhibited by FTS. FTS had no significant effects on lymphocyte subsets and immunity-related cells or on plasma superoxide dismutase activity and total glutathione level. The blood half-life time of exogenously injected FTS was short (2–3 min), indicating acute internalization of FTS into pancreatic β-cells. Our results suggested that FTS acutely and directly blocks some initial effect of alloxan, preventing the destruction of β-cells.</description><subject>Alloxan</subject><subject>Amino Acid Sequence</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Diabetes Mellitus, Experimental - prevention & control</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Dose-Response Relationship, Drug</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>FTS (facteur thymique sérique)</subject><subject>Glutathione - blood</subject><subject>Hyperglycemia - prevention & control</subject><subject>Injections, Intravenous</subject><subject>Islets of Langerhans - drug effects</subject><subject>Islets of Langerhans - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Molecular Sequence Data</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Spleen - drug effects</subject><subject>Spleen - pathology</subject><subject>Superoxide Dismutase - blood</subject><subject>Thymic Factor, Circulating - pharmacokinetics</subject><subject>Thymic Factor, Circulating - pharmacology</subject><subject>Thymic hormone</subject><subject>Thymic immunity</subject><subject>Tissue Distribution</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LAzEQhoMotX78A4U9iOhhNclms5uLKMUvKOhBzyEfszSyu6lJWuy_d2tLj54GZp53ZngQOiP4hmDCbzEmLKdCiCvBrgXmguR0D41JXYkcV4Tuo_EOOURHMX5hjEtByxEa1bimFS7H6P49wBL65Hyf-SazTmlIEDO9ytJs1TmTzXzofA-Z6zPVtv5H9XkKoBLYLKgUT9BBo9oIp9t6jD6fHj8mL_n07fl18jDNDStpyjWzBEjdNJwUpiSMCaVro63QlSFaceAFtaoptDa8qmtcGkMVJabgVg8NWxyjy83eefDfC4hJdi4aaFvVg19EWXEuSlaSAWQb0AQfY4BGzoPrVFhJguVanFxbkWsrUjD5J07SIXa-3b_QHdhdaGtqmF9s5yoa1TZB9cbFHcawqJhYX7_bYDC4WDoIMhoHvQHrApgkrXf___EL_dyJ0w</recordid><startdate>19940512</startdate><enddate>19940512</enddate><creator>Yamanouchi, Toshikazu</creator><creator>Moromizato, Hitoshi</creator><creator>Kojima, Shuhji</creator><creator>Shinohara, Takaomi</creator><creator>Sekino, Nori</creator><creator>Minoda, Susumu</creator><creator>Miyashita, Hideo</creator><creator>Akaoka, Ieo</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19940512</creationdate><title>Prevention of diabetes by thymic hormone in alloxan-treated rats</title><author>Yamanouchi, Toshikazu ; Moromizato, Hitoshi ; Kojima, Shuhji ; Shinohara, Takaomi ; Sekino, Nori ; Minoda, Susumu ; Miyashita, Hideo ; Akaoka, Ieo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-b4d1e18ff613c51449ab8cbd9b7c1ba6e632daf3bbc678805cc2a21c36db678d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Alloxan</topic><topic>Amino Acid Sequence</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Diabetes Mellitus, Experimental - prevention & control</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Dose-Response Relationship, Drug</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>FTS (facteur thymique sérique)</topic><topic>Glutathione - blood</topic><topic>Hyperglycemia - prevention & control</topic><topic>Injections, Intravenous</topic><topic>Islets of Langerhans - drug effects</topic><topic>Islets of Langerhans - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Molecular Sequence Data</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Spleen - drug effects</topic><topic>Spleen - pathology</topic><topic>Superoxide Dismutase - blood</topic><topic>Thymic Factor, Circulating - pharmacokinetics</topic><topic>Thymic Factor, Circulating - pharmacology</topic><topic>Thymic hormone</topic><topic>Thymic immunity</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamanouchi, Toshikazu</creatorcontrib><creatorcontrib>Moromizato, Hitoshi</creatorcontrib><creatorcontrib>Kojima, Shuhji</creatorcontrib><creatorcontrib>Shinohara, Takaomi</creatorcontrib><creatorcontrib>Sekino, Nori</creatorcontrib><creatorcontrib>Minoda, Susumu</creatorcontrib><creatorcontrib>Miyashita, Hideo</creatorcontrib><creatorcontrib>Akaoka, Ieo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamanouchi, Toshikazu</au><au>Moromizato, Hitoshi</au><au>Kojima, Shuhji</au><au>Shinohara, Takaomi</au><au>Sekino, Nori</au><au>Minoda, Susumu</au><au>Miyashita, Hideo</au><au>Akaoka, Ieo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevention of diabetes by thymic hormone in alloxan-treated rats</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>1994-05-12</date><risdate>1994</risdate><volume>257</volume><issue>1</issue><spage>39</spage><epage>46</epage><pages>39-46</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>We investigated the effects of facteur thymique sérique (FTS), a thymic peptide hormone, on alloxan- and streptozotocin-induced diabetes in rats. Pretreatment with intravenous injection of FTS significantly suppressed both alloxan- and streptozotocin-induced hyperglycemia. The effects of FTS were time dependent. FTS suppressed hyperglycemia in a dose range of 1–6600 μg/kg. Alloxan-induced hyperglycemia was completely prevented when FTS was injected in doses of 40–50 μg/kg 1 min before injection of alloxan. Histological examination of islet areas showed that alloxan-induced destruction of β-cells was inhibited by FTS. FTS had no significant effects on lymphocyte subsets and immunity-related cells or on plasma superoxide dismutase activity and total glutathione level. The blood half-life time of exogenously injected FTS was short (2–3 min), indicating acute internalization of FTS into pancreatic β-cells. Our results suggested that FTS acutely and directly blocks some initial effect of alloxan, preventing the destruction of β-cells.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>8082705</pmid><doi>10.1016/0014-2999(94)90691-2</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2999 |
| ispartof | European journal of pharmacology, 1994-05, Vol.257 (1), p.39-46 |
| issn | 0014-2999 1879-0712 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76695451 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Alloxan Amino Acid Sequence Animals Biological and medical sciences Diabetes Mellitus, Experimental - prevention & control Diabetes. Impaired glucose tolerance Dose-Response Relationship, Drug Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance FTS (facteur thymique sérique) Glutathione - blood Hyperglycemia - prevention & control Injections, Intravenous Islets of Langerhans - drug effects Islets of Langerhans - pathology Male Medical sciences Molecular Sequence Data Rats Rats, Wistar Spleen - drug effects Spleen - pathology Superoxide Dismutase - blood Thymic Factor, Circulating - pharmacokinetics Thymic Factor, Circulating - pharmacology Thymic hormone Thymic immunity Tissue Distribution |
| title | Prevention of diabetes by thymic hormone in alloxan-treated rats |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T15%3A44%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevention%20of%20diabetes%20by%20thymic%20hormone%20in%20alloxan-treated%20rats&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Yamanouchi,%20Toshikazu&rft.date=1994-05-12&rft.volume=257&rft.issue=1&rft.spage=39&rft.epage=46&rft.pages=39-46&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/0014-2999(94)90691-2&rft_dat=%3Cproquest_cross%3E76695451%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76695451&rft_id=info:pmid/8082705&rft_els_id=0014299994906912&rfr_iscdi=true |